STOCK TITAN

Nextcure Inc - NXTC STOCK NEWS

Welcome to our dedicated news page for Nextcure (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nextcure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nextcure's position in the market.

Rhea-AI Summary
NextCure, Inc. provided a business update, focusing on NC410 and LNCB74 therapies for ovarian and colorectal cancers. The company reported positive clinical data, financial results, and operational restructuring. Cash reserves of $108 million are expected to fund operations until the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.15%
Tags
earnings
-
Rhea-AI Summary
NextCure, Inc. (NXTC) announces the publication of a manuscript detailing the FLRT3-UNC5B Checkpoint Pathway's role in inhibiting T cell-based cancer immunotherapies. The study reveals FLRT3's function as an inhibitor of T cell activity and the potential of a FLRT3 monoclonal antibody to reverse these effects, offering new therapeutic avenues for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
clinical trial
-
Rhea-AI Summary
NextCure, Inc. (NXTC) presented preclinical data on a humanized monoclonal antibody targeting VSTM-1 for treating inflammatory airway disorders like COPD. The antibody has shown promise in reducing inflammation and preventing disease in animal models. NextCure is planning additional preclinical models and combination studies for other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
clinical trial
Rhea-AI Summary
NextCure, Inc. (Nasdaq: NXTC) announced the publication of a manuscript demonstrating the potential of NC605, a novel anti-Siglec-15 (S15) antibody, to prevent bone loss and preserve bone strength in animal models of severe immobilization resulting from acute spinal cord injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial
-
Rhea-AI Summary
NextCure, Inc. (Nasdaq: NXTC) provided an update on its clinical pipeline, including progress on NC410, LNCB74, NC762, and NC525. The company is actively seeking strategic partners to accelerate global development of its programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.31%
Tags
none
-
Rhea-AI Summary
NextCure, Inc. (NXTC) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference. The clinical-stage biopharmaceutical company will discuss its novel immunomedicines for cancer and immune-related diseases. The event will be live webcasted and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
Rhea-AI Summary
NextCure, Inc. (Nasdaq: NXTC) announced the publication of a manuscript in the Journal of Clinical Investigation detailing NC525's ability to induce cell death in acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs) through leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) agonism. The data demonstrate a unique apoptotic signaling pathway that specifically kills leukemic cells while sparing healthy hematopoietic stem cells (HSCs). NC525 holds great promise as a novel treatment for patients with resistant and refractory AML, synergizing with and improving the activity of the current standard-of-care therapy in AML. An update for the ongoing Phase 1a clinical trial is expected in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
clinical trial
-
Rhea-AI Summary
NextCure, Inc. provided a business update and reported Q3 2023 financial results. Updates on clinical programs, including Phase 1b trials of NC410 and NC762, and a Phase 1a operational update for NC525 are expected by year end. The company has approximately $118 million in cash, which is expected to fund operations into mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
earnings
-
Rhea-AI Summary
NextCure presents preclinical data on potential treatment for osteogenesis imperfecta at ASBMR Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
NextCure presents preclinical data on NC181, a novel antibody targeting ApoE4 for Alzheimer's disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
clinical trial
Nextcure Inc

Nasdaq:NXTC

NXTC Rankings

NXTC Stock Data

62.22M
22.76M
8.84%
43.13%
3.01%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Beltsville

About NXTC

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col